Inovio Pharmaceuticals GAAP EPS of -$1.45 misses by $0.19, revenue of $1.77M beats by $0.31M

• Inovio Pharmaceuticals press release (NASDAQ:INO): FY GAAP EPS of -$1.45 misses by $0.19.
• Revenue of $1.77M (-76.1% Y/Y) beats by $0.31M.
• Shares -5.56%.
• As of December 31, 2021, cash and cash equivalents and short-term investments were $401.3 million compared to $411.6 million as of December 31, 2020.
• Completed enrollment of REVEAL2, our second global Phase 3 clinical trial of VGX-3100 for cervical pre-cancer.
• Completed enrollment of Phase 1/2 trial of INO-3107, INOVIO's orphan drug designation therapeutic candidate for the treatment of Recurrent Respiratory Papillomatosis.

Comments

[smikhail]

"Because the World Can't Wait."